View Older Stories View More Recent Stories
-
Acadia Pharma (ACAD) Tops Q2 EPS by 2c
-
ACADIA names Scott Cenci as chief information and data officer
-
Acadia Pharmaceuticals (ACAD) PT Raised to $32 at UBS
-
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
RBC Capital Reiterates Outperform on Acadia Pharmaceuticals (ACAD) Following R&D Day
-
BMO Capital Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD)
-
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
-
Acadia Pharmaceuticals (ACAD) PT Raised to $38 at RBC Capital
-
Cantor Fitzgerald Reiterates Overweight Rating on Acadia Pharmaceuticals (ACAD)
-
Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent
-
Acadia Pharmaceuticals (ACAD) PT Raised to $30 at JPMorgan
-
Acadia Pharmaceuticals (ACAD) PT Raised to $23 at BofA Securities
-
Acadia Pharma (ACAD) Appoints Allyson McMillan-Youngblood as SVP, Rare Disease Franchise
-
Deutsche Bank Upgrades Acadia Pharmaceuticals (ACAD) to Buy
-
RBC Capital on Acadia Pharmaceuticals (ACAD): 'PWS Readout Asymmetrically Skewed to Upside'
-
BMO Capital on Acadia Pharmaceuticals (ACAD): 'IP Protection Pushes Target to $28'
-
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Morgan Stanley
-
Acadia Pharmaceuticals (ACAD) PT Raised to $32 at H.C. Wainwright
-
Acadia Pharma (ACAD) announces that Delaware Court has ruled in its favor for NUPLAZID litigation
-
Acadia Pharmaceuticals (ACAD) PT Raised to $19 at Oppenheimer
-
Acadia Pharmaceuticals (ACAD) IP Decision 'Removes a Key Overhang' - BMO Capital
-
Acadia Pharma (ACAD) Shares Gain After Ruling In Patent Case Vs Aurobindo - Bloomberg
-
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Files for 43.58M Share Offering by Selling Stockholders
-
Stifel Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD)
-
Acadia Pharma (ACAD) Tops Q1 EPS by 13c ; Offers Guidance
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Acadia Pharma (ACAD) reports inducement grants
-
Cantor Biotech industry report, buying value in RevGens
-
Acadia Pharma (ACAD) Announces Publication of Clinical Data from Open-Label DAFFODIL Study
-
Acadia Pharma (ACAD) and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
-
TD Cowen on Acadia Pharmaceuticals (ACAD): 'Expanded DAYBUE Salesforce to Drive LT Growth'
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $37 at Citizens JMP
-
Acadia Pharma (ACAD) Tops Q4 EPS by 64c ; Offers Guidance
-
Increasing unusual option volume: NVT ACAD VNET XRAY CBRE ANAB SWTX FEZ
-
Deutsche Bank Starts Acadia Pharmaceuticals (ACAD) at Hold
-
Acadia Pharma (ACAD) Provides Business and Pipeline Updates at J.P. Morgan Healthcare Conference
-
Acadia Pharma (ACAD) Submits Marketing Authorization Application to the EMA for Trofinetide for the Treatment of Rett Syndrome
-
Acadia Pharma (ACAD) 5400 contracts of February 19 calls trade
-
Acadia Pharma (ACAD) spikes on S&P 600 addition
-
Acadia Pharma (ACAD) to Join S&P SmallCap 600
-
Baird Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD), SAN711 deal is 'incrementally positive'
-
Acadia Pharma (ACAD) Enters Exclusive License Agreement with Saniona for SAN711
-
Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause
-
Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance
-
Acadia Pharma (ACAD) to Sell Rare Pediatric Disease Priority Review Voucher for $150M
